Forian Inc. (NASDAQ:FORA) is experiencing financial difficulties with a negative Return on Invested Capital (ROIC) of -13.42% and a ROIC to WACC ratio of -1.52, indicating it is not generating returns above its cost of capital.Peers such as Ikena Oncology, Inc. (IKNA), Finch Therapeutics Group, Inc. (FNCH), NeuroPace, Inc. (NPCE), Eledon Pharmaceuticals, Inc. (ELDN), and Werewolf Therapeutics, Inc. (HOWL) are also facing significant challenges, with negative ROIC to WACC ratios, highlighting an industry-wid ...

Core Insights - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 200 points on Wednesday [1] - Johnson Controls International PLC reported fourth-quarter results that exceeded analyst expectations for both earnings and revenue, leading to a significant rise in its stock price [1] Company Performance - Johnson Controls reported adjusted earnings per share of $1.26, surpassing the analyst consensus estimate of $1.20 [1] - The company's quarterly revenue reached $6.44 billion, exceeding the forecast of $6.32 billion [1] - Johnson Controls shares rose by 8% to $119.88 following the earnings report [2] Other Notable Stock Movements - Solid Power Inc saw a 55.7% increase in shares to $8.74 after reporting better-than-expected quarterly EPS results [4] - Babcock & Wilcox Enterprises Inc shares surged by 38.8% to $5.19 due to better-than-expected third-quarter EPS results [4] - Neuropace Inc's shares jumped 38.3% to $13.00 after raising its FY25 sales guidance above estimates [4] - Rigel Pharmaceuticals Inc experienced a 33.8% increase to $37.97 after reporting strong quarterly results and raising FY25 sales guidance [4] - Digital Turbine Inc gained 31.2% to $7.76 after better-than-expected second-quarter results and an increase in FY26 sales guidance [4] - Kennedy-Wilson Holdings Inc rose 31% to $9.79 following a proposal for acquisition at $10.25 per share [4] - Lemonade Inc's shares increased by 30.8% to $76.73 after reporting strong quarterly results and raising FY2025 sales guidance [4] - Teradata Corp gained 25.3% to $26.00 after better-than-expected third-quarter results and an increase in FY25 EPS guidance [4] - Lumentum Holdings Inc's shares rose 23.5% to $232.60 after reporting strong first-quarter results and issuing positive second-quarter guidance [4] - Teva Pharmaceutical Industries Ltd gained 21.5% to $24.85 after beating third-quarter earnings and revenue estimates [4] - Veracyte Inc rose 21.1% to $43.74 after better-than-expected third-quarter results and an increase in FY25 sales guidance [4] - Qualys Inc gained 20.5% to $146.05 after reporting strong quarterly results and raising FY25 guidance [4] - DigitalOcean Holdings Inc's shares increased by 18.6% to $45.99 after better-than-expected third-quarter results and an increase in FY25 sales guidance [4] - Rivian Automotive Inc gained 16.4% to $14.56 after reporting better-than-expected quarterly sales results [4] - Zeta Global Holdings Corp rose 14% to $19.04 after better-than-expected third-quarter results and issuing FY26 sales guidance [4] - Quantumscape Corp gained 13% to $17.47 [4] - Fubotv Inc rose 12.5% to $4.12 [4] - Diebold Nixdorf Inc gained 11.1% to $62.50 following positive earnings [4] - Fluence Energy Inc rose 11% to $21.28 [4] - Seagate Technology Holdings PLC gained 10.8% to $277.59 after announcing exchanges with holders of $500 million principal amount of exchangeable notes [4] - Toast Inc gained 9.3% to $39.00 after reporting better-than-expected quarterly results and receiving an upgraded price target from Morgan Stanley [4] - Marvell Technology Inc gained 6.5% to $93.29 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) increased by 52% to $2.24 [3] - Entravision Communications Corporation (EVC) rose by 33% to $2.66 [3] - Babcock & Wilcox Enterprises, Inc. (BW) saw a 28% increase to $4.79 [3] - NeuroPace, Inc. (NPCE) gained 24% reaching $11.71 [3] - Kennedy-Wilson Holdings, Inc. (KW) also increased by 24% to $9.30 [3] - Rigel Pharmaceuticals, Inc. (RIGL) rose by 22% to $34.72 [3] - Digital Turbine, Inc. (APPS) increased by 21% to $7.20 [3] - Lumentum Holdings Inc. (LITE) saw a 15% increase to $218.06 [3] - AsiaStrategy (SORA) rose by 14% to $3.63 [3] - Marine Petroleum Trust (MARPS) increased by 7% to $5.05 [3] Premarket Losers - Biohaven Ltd. (BHVN) decreased by 42% to $7.96 [4] - Trex Company, Inc. (TREX) fell by 34% to $30.65 [4] - Soleno Therapeutics, Inc. (SLNO) saw a 23% decline to $49.00 [4] - Axon Enterprise, Inc. (AXON) decreased by 19% to $572.00 [4] - Clover Health Investments, Corp. (CLOV) fell by 19% to $2.82 [4] - Pinterest, Inc. (PINS) decreased by 18% to $26.91 [4] - SSR Mining Inc. (SSRM) saw a 17% decline to $17.91 [4] - Upstart Holdings, Inc. (UPST) decreased by 16% to $38.81 [4] - WF International Limited (WXM) fell by 12% to $2.25 [4] - Corsair Gaming, Inc. (CRSR) decreased by 11% to $6.66 [4]

Core Insights - Several healthcare and biotech companies experienced significant after-hours stock price increases following the release of strong third-quarter earnings and updated guidance for 2025 [1] Company Summaries - **Veracyte Inc. (VCYT)**: - Stock surged 16.07% to $41.92 - Reported third-quarter net income of $19.1 million, a 26% increase year-over-year - Net earnings per share rose to $0.24, up $0.05, while non-GAAP EPS reached $0.51, an increase of $0.18 - Revenue totaled $131.9 million, reflecting 14% growth from $115.9 million in Q3 2024 [2][3] - **Rigel Pharmaceuticals, Inc. (RIGL)**: - Stock jumped 23.33% to $35.00 - Posted third-quarter net income of $27.9 million, more than doubling from $12.4 million last year - Earnings per share came in at $1.46 versus $0.70 last year - Total revenue for the quarter reached $69.5 million [4][5] - **NeuroPace, Inc. (NPCE)**: - Stock rose 16.28% to $10.93 - Reported a narrower net loss of $3.5 million compared to a $5.5 million loss in the same period last year - Revenue grew 30% year-over-year to $27.4 million, up from $21.1 million [6] - **CareDx, Inc. (CDNA)**: - Stock gained 8.47% to $15.75 - Reported GAAP net income of $1.7 million, compared to a $10.6 million loss in the prior-year period - GAAP earnings per share reached $0.03, reversing a $0.20 loss per share last year - Revenue increased 21% to $100.1 million [7][8] - **FibroBiologics, Inc. (FBLG)**: - Stock edged up 5.29% to $0.3443 - Experienced a modest after-hours gain despite a steep decline of over 17% during the regular session - No new financial disclosures were issued alongside the price movement [9]

Group 1: Earnings Performance - Stereotaxis Inc. reported a quarterly loss of $0.05 per share, better than the Zacks Consensus Estimate of a loss of $0.07, representing an earnings surprise of +28.57% [1] - The company posted revenues of $8.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 10.67%, compared to revenues of $4.5 million a year ago [2] - Over the last four quarters, Stereotaxis has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Stereotaxis shares have lost about 1.3% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.06 for the coming quarter and -$0.25 for the current fiscal year [4][7] - The current Zacks Rank for Stereotaxis is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which Stereotaxis belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Company Performance - PROCEPT BioRobotics Corporation reported a quarterly loss of $0.35 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, and an improvement from a loss of $0.50 per share a year ago, resulting in an earnings surprise of +14.63% [1] - The company posted revenues of $79.18 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.02%, but showing significant growth from year-ago revenues of $53.35 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - PROCEPT BioRobotics shares have declined approximately 40.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $83.74 million, and for the current fiscal year, it is -$1.49 on revenues of $325.61 million [7] Industry Outlook - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of stocks in this industry can be significantly influenced by the overall industry outlook, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Group 1: Earnings Performance - Orthofix reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and up from $0.05 per share a year ago, representing an earnings surprise of +225.00% [1] - The company posted revenues of $203.12 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.51% and up from $198.62 million year-over-year [2] Group 2: Stock Performance and Outlook - Orthofix shares have declined approximately 37.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $200.11 million, and for the current fiscal year, it is $0.49 on revenues of $811.9 million [7] Group 3: Industry Context - The Medical - Instruments industry, to which Orthofix belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

Core Viewpoint - NeuroPace, Inc. expects minimal impact from U.S. tariffs on its operations and financial results, maintaining its gross margin guidance for fiscal year 2025 [1][2]. Group 1: Financial Performance - The company will report its first quarter 2025 financial results on May 13, 2025, with a conference call scheduled for the same day [3]. - NeuroPace anticipates no material impact on gross margin for its DIXI Medical SEEG products, reiterating its gross margin guidance for 2025 [2]. Group 2: Business Operations - NeuroPace manufactures and sells most of its devices in the U.S., with limited supply chain activities outside the country, which contributes to the expected minimal impact from tariffs [2]. - The company has announced the termination of its SEEG distribution agreement with DIXI Medical effective October 1, 2025, followed by a six-month wind-down period [2]. Group 3: Company Overview - NeuroPace is focused on transforming the lives of people with epilepsy through its RNS System, which is the first commercially available brain-responsive platform for personalized treatment [4].

Core Insights - NeuroPace, Inc. announced three-year effectiveness data from the Post-Approval Study (PAS) of the RNS® System, showing an 82% median reduction in seizures for adults with drug-resistant focal epilepsy [1][6][7] - The data was presented at the American Academy of Neurology (AAN) Annual Meeting, highlighting the RNS System as the only FDA-approved device providing brain-responsive neurostimulation [2][3] Company Overview - NeuroPace is a medical device company focused on improving the lives of individuals with epilepsy through innovative solutions [5] - The RNS System is the first commercially available platform that delivers personalized, real-time treatment at the seizure source [5] Clinical Study Details - The PAS enrolled 324 patients across 32 centers, making it the largest FDA-reviewed, prospectively enrolled trial in neuromodulation for drug-resistant focal epilepsy [2][3] - The three-year effectiveness analysis indicated that 42% of patients remained seizure-free for over six months [6][7] Treatment Efficacy - The RNS System demonstrated a median seizure reduction of 62% at six months and 82% at three years [6][7] - The device provides greater seizure reduction compared to other neuromodulation therapies and is designed to offer personalized treatment [2][3]

Core Viewpoint - NeuroPace, Inc. is focused on addressing the unmet medical needs of patients with drug-resistant focal epilepsy (DRE) through its innovative RNS® System, which will be presented at the AAN 2025 Annual Meeting [1][2]. Company Overview - NeuroPace is a commercial-stage medical device company based in Mountain View, California, dedicated to transforming the lives of people with epilepsy by reducing or eliminating debilitating seizures [5]. - The RNS System is the first and only commercially available brain-responsive platform that provides personalized, real-time treatment at the seizure source, aiming to improve care standards for patients with DRE [5]. Upcoming Events - NeuroPace will present data from the Post-Approval Study (PAS) of the RNS System at the AAN 2025 Annual Meeting in San Diego from April 5 to 9, with a specific oral presentation scheduled for April 7 [1][7]. - The RNS System will be showcased at booth 1642 during the event [2][4]. Leadership Insights - Joel Becker, CEO of NeuroPace, emphasized the significant unmet medical need for patients with DRE and expressed the company's commitment to improving outcomes for this population [2].